Asset profile
Ferric derisomaltose · Monoferric / Monofer
Other
Evidence outlook
Approved: Chronic Kidney Disease, Heart Failure
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 109 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ferric Derisomaltose (Monoferric / Monofer): this drug | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Etelcalcetide (Parsabiv) | Approved | Peptide | Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells | ||
| Extended-Release Calcifediol (Rayaldee) | Approved | Small molecule | Vitamin D receptor (VDR), via conversion to calcitriol | ||
| Ferric Pyrophosphate Citrate (Triferic) | Approved | Small molecule | Iron-replacement therapy delivered via dialysate | ||
| Ferumoxytol (Feraheme) | Approved | Nanoparticle | IV iron replacement therapy | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
November 2026 (1)
What to watch
December 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (6)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (1)
What to watch
October 2027 (2)
December 2027 (1)
What to watch
2028 (4)
September 2028 (2)
What to watch
What to watch
October 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (1)
July 2029 (1)
What to watch
2030 (2)
August 2030 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.